Chikungunya infected children are being reported these days, said Dr. Deepal Perera, a specialist at the Lady Ridgeway ...

Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...

Cases of Chikungunya among children are being reported in recent days, Lady Ridgeway Hospital’s Consultant Paediatrician Dr. Deepal Perera said. Dr.

Seventy-two case have been diagnosed as confirmed GBS cases and 20 patients are currently on ventilators, it said. So far, ...

Valneva has announced positive outcomes from its Phase III trial of the single-shot IXCHIQ chikungunya virus vaccine in ...

This action follows an executive order signed by President Trump on his first day in office to withdraw the United States ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Bhopal: AIIMS Bhopal department of microbiology has secured NABL accreditation. The department stands out for having two NABL ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ®, ...

Valneva has shared positive results from a late-stage study of its single-dose chikungunya vaccine in adolescents aged 12 to ...

Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its ...

Valneva (VALN) stock rose after the company posted new Phase 3 trial data for its chikungunya vaccine, Ixchiq, in adolescents aged 12-17. Read more here.